Exco InTouch Shortlisted For The Best Technological Development In Clinical Trials 2014 SCRIP Award

Selection for the accolade shortlist recognizes the company’s mDNA® technology project team – leading the way with groundbreaking innovation in the field of patient engagement and data capture solutions to enhance efficiencies in clinical trials

01 October 2014 – Exco InTouch, the leading provider of digital patient engagement and data capture solutions for clinical research and healthcare providers, today announced that its mDNA® technology project team have been shortlisted for the “Best Technological Development in Clinical Trials” category for the 2014 SCRIP Awards.

The innovative technology is a diagnostic and data handling tool providing secure and anonymous data communication and storage for clinical trials. Through interrogating the device in use, mDNA® facilitates a BYOD (Bring Your Own Device) approach in clinical research, as well as enabling content to be displayed appropriately, enhancing the familiarity and usability for each trial participant. Moreover, mDNA® supports essential data security and privacy controls by segregating Personally Identifiable Information (PII) in accordance EU Data Protection, Safe Harbor, and HIPAA data protection regulations.

As a leading electronic Clinical Outcomes Assessment (eCOA) and electronic Patient Reported Outcomes (ePRO) provider, Exco InTouch is committed to developing novel technology, like mDNA®, and to driving innovation to improve clinical trials to the benefit of both clinicians and patients. Exemplifying the company’s commitment to technological development, Exco InTouch recently unveiled further innovation by announcing that it is the only eCOA provider to have published native apps on all major mobile operating platforms, including iOS, Android and Windows8.

Tim Davis, CEO and founder of Exco InTouch commented: “We are delighted to have been shortlisted for this award. Indeed, we have an established track record for driving technological innovation in the field of digital data capture and patient engagement solutions in order to optimize efficiencies in clinical trials to the benefit of both clinicians and patients. Our proprietary mDNA® technology is a prime example of this and we are pleased that it has received such industry recognition. We look forward to continuing to take a lead in this critically important area”.

For media enquiries, please contact Tristan Jervis or Alex Heeley on +44 (0) 207 203 6740 or e-mail: t.jervis@defacto.com.

Help employers find you! Check out all the jobs and post your resume.

MORE ON THIS TOPIC